| Etonogestrel | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | |
| Etonogestrel | hsa00030 | Pentose phosphate pathway | 8.97E-03 | 1 | P11413 | G6PD | More | |
| Etonogestrel | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
| Etonogestrel | hsa00220 | Arginine biosynthesis | 4.88E-02 | 1 | P49448 | GLUD2 | More | |
| Etonogestrel | hsa00250 | Alanine, aspartate and glutamate metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | |
| Etonogestrel | hsa00471 | D-Glutamine and D-glutamate metabolism | 1.65E-02 | 1 | P49448 | GLUD2 | More | |
| Etonogestrel | hsa00480 | Glutathione metabolism | 1.35E-02 | 1 | P11413 | G6PD | More | |
| Etonogestrel | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Etonogestrel | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
| Etonogestrel | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Etonogestrel | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Etonogestrel | hsa00910 | Nitrogen metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | |
| Etonogestrel | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | |
| Etonogestrel | hsa01200 | Carbon metabolism | 2.91E-02 | 1 | P11413 | G6PD | More | |
| Etonogestrel | hsa01210 | 2-Oxocarboxylic acid metabolism | 3.43E-02 | 1 | P50213 | IDH3A | More | |
| Etonogestrel | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | |
| Etonogestrel | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Etonogestrel | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
| Etonogestrel | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | |
| Etonogestrel | hsa03060 | Protein export | 3.28E-02 | 1 | Q15070 | OXA1L | More | |
| Etonogestrel | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
| Etonogestrel | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | |
| Etonogestrel | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04015 | Rap1 signaling pathway | 5.18E-04 | 3 | P08069, P06213, O00522 | IGF1R, INSR, KRIT1 | More | |
| Etonogestrel | hsa04024 | cAMP signaling pathway | 4.25E-03 | 7 | P63092, P42338, P26678, P0DP23, P61586, Q13370, Q13009 | GNAS, PIK3CB, PLN, CALM1, RHOA, PDE3B, TIAM1 | More | |
| Etonogestrel | hsa04064 | NF-kappa B signaling pathway | 4.58E-03 | 4 | Q13489, Q13546, Q9UDY8, Q9UNE0 | BIRC3, RIPK1, MALT1, EDAR | More | |
| Etonogestrel | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | |
| Etonogestrel | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | |
| Etonogestrel | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
| Etonogestrel | hsa04114 | Oocyte meiosis | 3.19E-03 | 5 | P51812, Q02750, P16298, Q17RY0, P08069 | RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | |
| Etonogestrel | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Etonogestrel | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
| Etonogestrel | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04141 | Protein processing in endoplasmic reticulum | 2.78E-02 | 3 | P07384, O95487, O95816 | CAPN1, SEC24B, BAG2 | More | |
| Etonogestrel | hsa04150 | mTOR signaling pathway | 7.74E-03 | 4 | P08069, Q02750, Q9NQL2, P51812 | IGF1R, MAP2K1, RRAGD, RPS6KA3 | More | |
| Etonogestrel | hsa04152 | AMPK signaling pathway | 2.07E-03 | 3 | P08069, Q96EB6, P36956 | IGF1R, SIRT1, SREBF1 | More | |
| Etonogestrel | hsa04211 | Longevity regulating pathway | 1.34E-03 | 4 | Q12778, P08069, Q9UEF7, Q96KQ7 | FOXO1, IGF1R, KL, EHMT2 | More | |
| Etonogestrel | hsa04213 | Longevity regulating pathway - multiple species | 1.66E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Etonogestrel | hsa04217 | Necroptosis | 1.85E-03 | 7 | P01375, P01568, P48023, Q13489, Q13546, Q14765, Q99878 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT4, H2AC14 | More | |
| Etonogestrel | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
| Etonogestrel | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | |
| Etonogestrel | hsa04360 | Axon guidance | 7.48E-04 | 5 | P20827, O95631, P42338, P23528, Q06124 | EFNA1, NTN1, PIK3CB, CFL1, PTPN11 | More | |
| Etonogestrel | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Etonogestrel | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Etonogestrel | hsa04510 | Focal adhesion | 8.84E-03 | 4 | O14986, P61586, Q16363, P08069 | PIP5K1B, RHOA, LAMA4, IGF1R | More | |
| Etonogestrel | hsa04520 | Adherens junction | 1.65E-05 | 4 | P08069, P19784, P67870, P61586 | IGF1R, CSNK2A2, CSNK2B, RHOA | More | |
| Etonogestrel | hsa04530 | Tight junction | 2.08E-02 | 3 | P63261, Q9Y478, Q92974 | ACTG1, PRKAB1, ARHGEF2 | More | |
| Etonogestrel | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
| Etonogestrel | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
| Etonogestrel | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Etonogestrel | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Etonogestrel | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
| Etonogestrel | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | |
| Etonogestrel | hsa04659 | Th17 cell differentiation | 3.99E-03 | 7 | P25963, P42224, P14784, P40189, P84022, Q13485, P08238 | NFKBIA, STAT1, IL2RB, IL6ST, SMAD3, SMAD4, HSP90AB1 | More | |
| Etonogestrel | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | |
| Etonogestrel | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | |
| Etonogestrel | hsa04714 | Thermogenesis | 1.25E-02 | 3 | P15336, P63261, Q9Y478 | ATF2, ACTG1, PRKAB1 | More | |
| Etonogestrel | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Etonogestrel | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
| Etonogestrel | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Etonogestrel | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | |
| Etonogestrel | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
| Etonogestrel | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
| Etonogestrel | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa04913 | Ovarian steroidogenesis | 8.40E-04 | 2 | P06213, P08069 | INSR, IGF1R | More | |
| Etonogestrel | hsa04914 | Progesterone-mediated oocyte maturation | 9.67E-04 | 7 | P08069, Q17RY0, P42338, Q13370, P08238, P51812, Q02750 | IGF1R, CPEB4, PIK3CB, PDE3B, HSP90AB1, RPS6KA3, MAP2K1 | More | |
| Etonogestrel | hsa04920 | Adipocytokine signaling pathway | 2.80E-02 | 2 | Q06124, Q9Y478 | PTPN11, PRKAB1 | More | |
| Etonogestrel | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | |
| Etonogestrel | hsa04924 | Renin secretion | 3.77E-02 | 2 | Q13370, P0DP23 | PDE3B, CALM1 | More | |
| Etonogestrel | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | |
| Etonogestrel | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Etonogestrel | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Etonogestrel | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Etonogestrel | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
| Etonogestrel | hsa04964 | Proximal tubule bicarbonate reclamation | 4.88E-02 | 1 | P49448 | GLUD2 | More | |
| Etonogestrel | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | |
| Etonogestrel | hsa04975 | Fat digestion and absorption | 9.50E-04 | 1 | O14494 | PLPP1 | More | |
| Etonogestrel | hsa05032 | Morphine addiction | 2.47E-03 | 3 | P62873, P48169, P63092 | GNB1, GABRA4, GNAS | More | |
| Etonogestrel | hsa05130 | Pathogenic Escherichia coli infection | 9.80E-03 | 4 | Q92974, P63261, Q06124, O95487 | ARHGEF2, ACTG1, PTPN11, SEC24B | More | |
| Etonogestrel | hsa05132 | Salmonella infection | 5.76E-04 | 7 | P25963, Q13546, Q13489, P10415, Q9BQS8, O60282, P68371 | NFKBIA, RIPK1, BIRC3, BCL2, FYCO1, KIF5C, TUBB2C | More | |
| Etonogestrel | hsa05140 | Leishmaniasis | 4.50E-03 | 5 | P14598, O60603, P25963, P29350, Q15080 | NCF1, TLR2, NFKBIA, PTPN6, NCF4 | More | |
| Etonogestrel | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Etonogestrel | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Etonogestrel | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Etonogestrel | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Etonogestrel | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | |
| Etonogestrel | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
| Etonogestrel | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | |
| Etonogestrel | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
| Etonogestrel | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | |
| Etonogestrel | hsa05202 | Transcriptional misregulation in cancer | 2.82E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Etonogestrel | hsa05211 | Renal cell carcinoma | 1.06E-02 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | |
| Etonogestrel | hsa05212 | Pancreatic cancer | 1.44E-03 | 5 | P42338, P42224, P84022, Q13485, O75293 | PIK3CB, STAT1, SMAD3, SMAD4, GADD45B | More | |
| Etonogestrel | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
| Etonogestrel | hsa05214 | Glioma | 1.88E-03 | 4 | P08069, P0DP23, P42338, O75293 | IGF1R, CALM1, PIK3CB, GADD45B | More | |
| Etonogestrel | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
| Etonogestrel | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
| Etonogestrel | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Etonogestrel | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
| Etonogestrel | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | |
| Etonogestrel | hsa05226 | Gastric cancer | 4.33E-03 | 5 | Q02750, O15169, P84022, Q13485, P10415 | MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | |
| Etonogestrel | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | |
| Etonogestrel | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
| Etonogestrel | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Etonogestrel | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Etonogestrel | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
| Etonogestrel | hsa05415 | Diabetic cardiomyopathy | 3.59E-02 | 1 | P11413 | G6PD | More | |
| Etonogestrel | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |
